Order Article Reprints

Flaadt T, Rehm J, Simon T, Hero B, Ladenstein RL, Lode HN, Grabow D, Nolte S, Crazzolara R, Greil J, et al. Long-Term Outcomes and Quality of Life of High-Risk Neuroblastoma Patients Treated with a Multimodal Treatment Including Anti-GD2 Immunotherapy: A Retrospective Cohort Study. Cancers. 2025; 17(1):149. https://doi.org/10.3390/cancers17010149

Flaadt, Tim, Jonas Rehm, Thorsten Simon, Barbara Hero, Ruth L. Ladenstein, Holger N. Lode, Desiree Grabow, Sandra Nolte, Roman Crazzolara, Johann Greil, and et al. 2025. "Long-Term Outcomes and Quality of Life of High-Risk Neuroblastoma Patients Treated with a Multimodal Treatment Including Anti-GD2 Immunotherapy: A Retrospective Cohort Study" Cancers 17, no. 1: 149. https://doi.org/10.3390/cancers17010149

Flaadt, T., Rehm, J., Simon, T., Hero, B., Ladenstein, R. L., Lode, H. N., Grabow, D., Nolte, S., Crazzolara, R., Greil, J., Ebinger, M., Abele, M., Holzer, U., Döring, M., Schulte, J. H., Bader, P., Schlegel, P.-G., Eyrich, M., Lang, P., ... Handgretinger, R. (2025). Long-Term Outcomes and Quality of Life of High-Risk Neuroblastoma Patients Treated with a Multimodal Treatment Including Anti-GD2 Immunotherapy: A Retrospective Cohort Study. Cancers, 17(1), 149. https://doi.org/10.3390/cancers17010149